Encodes An Enzyme Patents (Class 536/23.2)
  • Patent number: 8936929
    Abstract: The present invention relates to novel xylose-fermenting yeast strains (for example, yeast of the genus Saccharomyces, e.g., S. cerevisiae) with an enhanced ability to ferment the xylose (and/or another pentose sugar) present in a lignocellulosic hydrolysate to a fermentation product(s) (for example, an alcohol (e.g., ethanol) or a sugar alcohol (e.g., xylitol)).
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: January 20, 2015
    Assignee: Iogen Energy Corporation
    Inventors: Jennifer Donaldson, Jan-Maarten A. Geertman, Glenn D. Munkvold, Gary Pigeau, Philippe J. Dufresne, Loreta Gudynaite-Savitch
  • Patent number: 8937170
    Abstract: The present invention is related to a fungal serine protease enzyme, which comprises an amino acid sequence of the mature Fe_RF6318 enzyme having an amino acid sequence of SEQ ID NO: 15. The serine protease is obtainable from Fusarium equiseti, more preferably from the deposited strain CBS 119568. Also disclosed are nucleic acid sequences encoding said protease, such as plasmid pALK2521 comprising the nucleotide sequence SEQ ID NO:9 deposited in E. coli RF7664 under accession number DSM 22171 and plasmid pALK2529 comprising the full-length gene SEQ ID NO: 10 deposited in E. coli RF7800 under accession number DSM 22172. Said protease is useful as an enzyme preparation applicable in detergent compositions and for treating fibers, for treating wool, for treating hair, for treating leather, for treating food or feed, or for any applications involving modification, degradation or removal of proteinaceous material.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: January 20, 2015
    Assignee: AB Enzymes Oy
    Inventors: Kari Juntunen, Leena Valtakari, Susanna Makinen, Jarno Kallio, Jari Vehmaanpera, Pentti Ojapalo, Marja Paloheimo
  • Publication number: 20150017197
    Abstract: Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a/1b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.
    Type: Application
    Filed: September 8, 2014
    Publication date: January 15, 2015
    Inventors: David B. Weiner, Krystle A. Lang, Jian Yan, Ruxandra Draghia-Akli, Amir Khan
  • Publication number: 20150020233
    Abstract: The invention provides glyphosate tolerant transgenic turfgrass plants, plant material, and seeds that have a specific transformation event. Also provided are assays for detecting the presence of the event. The invention also provides sequences for a variant EPSPS gene and a GAO2X gene, cassettes, and plants comprising the variant EPSPS gene and a GAO2X gene.
    Type: Application
    Filed: July 14, 2014
    Publication date: January 15, 2015
    Inventors: Robert W. HARRIMAN, Lisa LEE, David M. STALKER, Rebecca TORISKY
  • Publication number: 20150017691
    Abstract: The present invention relates to a polypeptide which has ?-glucosidase activity, and which includes an amino acid sequence represented by SEQ ID NO: 1, a polypeptide including an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence represented by SEQ ID NO: 1, or a polypeptide including an amino acid sequence having 92% or greater sequence identity with the amino acid sequence represented by SEQ ID NO: 1. According to the present invention, a novel ?-glucosidase enzyme derived from Acremonium cellulolyticus, a polynucleotide encoding the ?-glucosidase, an expression vector for expressing the ?-glucosidase, a transformant incorporated with that expression vector, and a method for producing a cellulose degradation product using the ?-glucosidase can be provided.
    Type: Application
    Filed: July 7, 2014
    Publication date: January 15, 2015
    Inventors: Maiko TANAKA, Shigenobu MITSUZAWA, Satoru SHINKAWA, Daisuke SHIBATA, Takeshi ARA, Migiwa TAKEDA
  • Publication number: 20150017692
    Abstract: The present invention relates to a polypeptide which has ?-glucosidase activity, and which includes an amino acid sequence represented by SEQ ID NO: 1, a polypeptide including an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence represented by SEQ ID NO: 1, or a polypeptide including an amino acid sequence having 92% or greater sequence identity with the amino acid sequence represented by SEQ ID NO: 1. According to the present invention, a novel ?-glucosidase enzyme derived from Acremonium cellulolyticus, a polynucleotide encoding the ?-glucosidase, an expression vector for expressing the ?-glucosidase, a transformant incorporated with that expression vector, and a method for producing a cellulose degradation product using the ?-glucosidase can be provided.
    Type: Application
    Filed: July 7, 2014
    Publication date: January 15, 2015
    Inventors: Maiko TANAKA, Shigenobu MITSUZAWA, Satoru SHINKAWA, Daisuke SHIBATA, Takeshi ARA, Migiwa TAKEDA
  • Publication number: 20150017701
    Abstract: Hybrid alpha-amylases are provided that share a conserved 3D structure in whole or in part with a wild-type Termamyl-like ?-amylase, e.g., a Bacillus amylase. In the hybrid, an N-terminal portion of a Termamyl-like ?-amylase is replaced with sequences from an archae ?-amylase. The sequence similarity between the two amylase sequences may be less than 60%. Conserving the wild-type 3D structure in the hybrid facilitates obtaining enzymatically active amylases. In one embodiment, one or both amylase sequences contribute residues to the B domain, resulting in particularly advantageous properties. For instance, replacement of the Ca2+ binding site in the B domain of the Termamyl-like ?-amylase with a B domain sequence of an archae ?-amylase that does not bind Ca2+ can produce a hybrid that is fully active in the absence of Ca2+.
    Type: Application
    Filed: July 25, 2014
    Publication date: January 15, 2015
    Applicant: DANISCO US INC.
    Inventors: Scott D. Power, Andrew Shaw
  • Publication number: 20150020238
    Abstract: The present invention provides a synthetic gene encoding the human enterokinase light chain protein, a recombinant vector comprising the synthetic gene encoding the protein, a plant cell transformed with the recombinant vector, a method for producing the human enterokinase light chain protein in a plant by using the recombinant vector, a method for producing a plant producing the human enterokinase light chain protein by transforming a plant cell with the recombinant vector, a plant producing the human enterokinase light chain protein which is produced by the method, and a seed thereof, and a composition for large-scale production of the human enterokinase light chain protein in a plant, in which the composition comprises the synthetic gene encoding the human enterokinase light chain protein.
    Type: Application
    Filed: July 19, 2012
    Publication date: January 15, 2015
    Applicant: NBM CO., LTD.
    Inventor: Tae Ho Kwon
  • Publication number: 20150018522
    Abstract: Disclosed are mutants of galactosyltransferases that can catalyze formation of oligosaccharides in the presence of magnesium; mutants of galactosyltransferases having altered donor and acceptor specificity which can catalyze formation of oligosaccharides in the presence of magnesium; methods and compositions that can be used to synthesize oligosaccharides; methods for increasing the immunogenicity of an antigen; and methods to stabilize platelets.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 15, 2015
    Applicant: The United States of America, as represented by the Secretary, Department of Health & Human Servic
    Inventors: Pradman K. Qasba, Elizabeth Boeggeman, Boopathy Ramakrishnan
  • Publication number: 20150020235
    Abstract: A method for carrying out recombination at a target locus in a Rasamsonia cell, which method comprises: providing two or more nucleic acids which, when taken together, comprise: (a) sequences capable of homologous recombination with sequences flanking the target locus; (b) two or more site-specific recombination sites; (c) a sequence encoding a recombinase which recognizes the site-specific recombination sites; and (d) a sequence encoding a marker, wherein the two or more nucleic acids are capable of homologous recombination with each other so as to give rise to a single nucleic acid, and wherein at least two of the two or more nucleic acids each comprise a sequence encoding a non-functional portion of the marker; and recombining in a Rasamsonia cell the said two or more nucleic acids with each other and with the sequences flanking the target locus so that a contiguous nucleic acid sequence encoding a functional marker and the sequence encoding the recombinase are inserted at the target locus, said marker-enc
    Type: Application
    Filed: March 12, 2013
    Publication date: January 15, 2015
    Inventors: Alrik Pieter Los, Yvonne Johannes Odilia Arendsen, Adrianus Wilhelmus Hermanus Vollebregt
  • Publication number: 20150017695
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.
    Type: Application
    Filed: September 30, 2014
    Publication date: January 15, 2015
    Inventors: Jack Liang, Stephane J. Jenne, Emily Mundorff, Charlene Ching, John M. Gruber, Anke Krebber, Gjalt W. Huisman
  • Publication number: 20150020221
    Abstract: The invention provides methods and compositions for enhancing the efficacy of cancer therapies through modulation of BAL1 and/or BBAP. Also provided are methods for predicting the efficacy of cancer therapies or treating cancer in a subject through modulation of BAL1 and/or BBAP. Further provided are methods for identifying compounds that are capable of modulating BAL1-BBAP complexes.
    Type: Application
    Filed: October 5, 2012
    Publication date: January 15, 2015
    Inventors: Margaret A. Shipp, Qingsheng Yan
  • Publication number: 20150020234
    Abstract: The invention relates to isolated nucleic acids encoding a feruloyl-CoA:monolignol transferase and feruloyl-CoA:monolignol transferase enzymes. The isolated nucleic acids and/or the enzymes enable incorporation of monolignol ferulates into the lignin of plants, where such monolignol ferulates include, for example, p-coumaryl ferulate, coniferyl ferulate, and/or sinapyl ferulate. The invention also includes methods and plants that include nucleic acids encoding a feruloyl-CoA:monolignol transferase enzyme and/or feruloyl-CoA:monolignol transferase enzymes.
    Type: Application
    Filed: October 4, 2012
    Publication date: January 15, 2015
    Inventors: Curtis Wilkerson, John Ralph, Saunia Withers
  • Publication number: 20150017728
    Abstract: The present invention provides compositions and methods for targeted cleavage of cellular chromatin in a region of interest and/or homologous recombination at a predetermined site in cells. Compositions include fusion polypeptides comprising a TAL effector binding or a zinc finger domain and an I-TevI homing endonuclease cleavage domain as well as nucleic acid sequence encoding the same. The use of the I-TevI domain allows for monomer endonuclease sequences to achieve cleavage of cellular chromatin and represents an advantage over prior endonucleases which require self-dimerization, and two nucleases with appropriate spacers.
    Type: Application
    Filed: September 19, 2012
    Publication date: January 15, 2015
    Inventors: Bing Yang, Ting Li, Sheng Huang
  • Publication number: 20150017689
    Abstract: The present invention relates to a polypeptide which has ?-glucosidase activity, and which includes an amino acid sequence represented by SEQ ID NO: 1, a polypeptide including an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence represented by SEQ ID NO: 1, or a polypeptide including an amino acid sequence having 90% or greater sequence identity with the amino acid sequence represented by SEQ ID NO: 1. According to the present invention, a novel ?-glucosidase enzyme derived from Acremonium cellulolyticus, a polynucleotide encoding the ?-glucosidase, an expression vector for expressing the ?-glucosidase, a transformant incorporated with that expression vector, and a method for producing a cellulose degradation product using the ?-glucosidase can be provided.
    Type: Application
    Filed: July 3, 2014
    Publication date: January 15, 2015
    Inventors: Maiko TANAKA, Shigenobu MITSUZAWA, Satoru SHINKAWA, Daisuke SHIBATA, Takeshi ARA, Migiwa TAKEDA
  • Patent number: 8933297
    Abstract: The invention provides Nicotiana benthamiana mutant plants which are incapable of forming xylosyl-structures on glycoproteins. In addition, the invention provides methods for the production of heterologous glycoproteins in said mutant plants.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: January 13, 2015
    Assignee: Icon Genetics GmbH
    Inventors: Koen Weterings, Gerben Van Eldik
  • Patent number: 8932835
    Abstract: A process for the enantioselective enzymatic reduction of a keto compound of general formula I wherein R may represent any protective group for amino functions (tert. butyloxycarbonyl group (BOC), benzyloxycarbonyl group, 9-fluorenylmethoxycarbonyl group) and X?—Cl, —CN, —OH, Br, F.
    Type: Grant
    Filed: September 22, 2008
    Date of Patent: January 13, 2015
    Assignee: IEP GmbH
    Inventors: Antje Gupta, Maria Bobkova, Anke Tschentscher
  • Patent number: 8932836
    Abstract: The disclosure provides transaminase polypeptides capable of converting the substrate, 2-(3,4-dimethoxyphenethoxy)cyclohexanone to the trans diastereomer product (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine in at least a 2:1 diastereomeric ratio relative to the cis diastereomer (1R,2S)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine. The disclosure also provides polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides in processes for preparing (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine and its analogs, which can product compounds can be further used to prepare the aminocyclohexylether compound, (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol, which is an ion channel blocker.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: January 13, 2015
    Assignee: Codexis, Inc.
    Inventors: John Limanto, Gregory Beutner, Brendan Grau, Jacob Janey, Artis Klapars, Eric R. Ashley, Hallena R. Strotman, Matthew D. Truppo, Gregory Hughes, Fabien Cabirol, Anupam Gohel, Steven J. Collier, Jack Liang, Marissa Mock, Emily Mundorff, Scott Novick, Derek Smith
  • Patent number: 8932845
    Abstract: An isopropyl alcohol-producing Escherichia coli equipped with an isopropyl alcohol production system, having at least one enhanced enzyme activity selected from the group consisting of an enhanced malate dehydrogenase activity, an enhanced NAD(P)+ transhydrogenase (AB-specific) activity, and an enhanced thiolase activity, and an isopropyl alcohol producing method including producing isopropyl alcohol from a plant-derived raw material using the isopropyl alcohol-producing Escherichia coli.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: January 13, 2015
    Assignee: Mitsui Chemicals, Inc.
    Inventors: Yoshiko Matsumoto, Junichiro Hirano, Takashi Morishige, Tomokazu Shirai, Hitoshi Takahashi, Koh Amano, Nozomi Takebayashi, Mitsufumi Wada, Hiroshi Shimizu, Chikara Furusawa, Takashi Hirasawa
  • Patent number: 8933300
    Abstract: The invention relates to novel elongase genes with the sequences stated in sequence SEQ ID NO:1, SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7 or their homologs, derivatives or analogs, to a gene construct comprising this gene or its homologs, derivatives and analogs, and to its use. The invention also relates to vectors or transgenic organisms comprising an elongase gene with the sequence SEQ ID NO:1, SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7 or its homologs, derivatives and analogs. The invention furthermore relates to the use of the elongase gene sequences alone or in combination with further elongases and/or further fatty acid biosynthesis genes. The present invention relates to a novel elongase gene with the sequence SEQ ID NO:1 or its homologs, derivatives and analogs.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: January 13, 2015
    Assignee: BASF Aktiengesellschaft
    Inventors: Ernst Heinz, Thorsten Zank, Ulrich Zähringer, Jens Lerchl, Andreas Renz
  • Patent number: 8932586
    Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: January 13, 2015
    Assignee: Intrexon Corporation
    Inventors: Timothy David Jones, Francis Joseph Carr
  • Patent number: 8932861
    Abstract: The present invention relates to a transformation vector comprising the partial fragments of a gene encoding transposase, a microorganism transformed with the vector, and a method of producing lysine using the microorganism.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: January 13, 2015
    Assignee: CJ Cheiljedang Corporation
    Inventors: Jae-Woo Jang, Sang-Jo Lim, Jong-Soo Choi, Chul-Ha Kim, Jun-Ok Moon
  • Publication number: 20150010532
    Abstract: The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 8, 2015
    Inventor: Wayne K. Herber
  • Publication number: 20150010529
    Abstract: Modified PH20 hyaluronidase polypeptides that exhibit stability and activity under thermal stress conditions are provided. Also provided are compositions and formulations and uses thereof.
    Type: Application
    Filed: July 3, 2014
    Publication date: January 8, 2015
    Inventor: Ge Wei
  • Publication number: 20150011743
    Abstract: The present invention relates to protein engineering, and concerns especially family G/11 xylanases, and genes encoding said enzymes. In specific, the invention concerns Trichoderma reesei XYNII gene, which codes for endo-1,4-?-xylanase (EC 3.2.1.8). The invention describes how site-directed mutagenesis can be used to improve the properties of an enzyme to match the industrial conditions where it is used. Protein engineering can be used to improve thermoactivity and thermostability of xylanases, as well as to broaden their pH range.
    Type: Application
    Filed: September 16, 2014
    Publication date: January 8, 2015
    Applicant: DANISCO US INC.
    Inventors: Fred FENEL, Ossi TURUNEN, Matti LEISOLA
  • Publication number: 20150010527
    Abstract: Plant-expressed human recombinant DNase proteins, nucleic acid constructs for expression of the human recombinant DNase I in plant cells, cells expressing the nucleic acid construct and therapeutic uses thereof are disclosed. Particularly, compositions and methods for treating pulmonary and/or respiratory conditions by inhalation of the plant-expressed human recombinant DNase I are provided.
    Type: Application
    Filed: January 31, 2013
    Publication date: January 8, 2015
    Inventors: Yoseph Shaaltiel, Uri Hanania, Tali Kizhner, Yulia Matiuhin, Liat Fux, Avidor Shulman
  • Publication number: 20150010556
    Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.
    Type: Application
    Filed: July 2, 2014
    Publication date: January 8, 2015
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
  • Publication number: 20150010947
    Abstract: Methods and systems for creating a genetic construct, a protein, and a polymer comprising a domain swapping module. A domain swapping module is a fusion protein in which a lever protein, which has a long amino (N) to carboxy (C) terminal distance, is inserted into a surface loop of an assembler protein, thereby stretching the assembler protein and splitting it into two fragments held apart by the lever so that they cannot rejoin. If the assembler protein is split at the proper location, the fragments will recombine with their respective counterparts from either one or more different—but similarly-split—assembler proteins.
    Type: Application
    Filed: December 27, 2012
    Publication date: January 8, 2015
    Applicant: The Research Foundation For The State University Of New York
    Inventors: Stewart Loh, Jeung-hio Ha, Diana Mitrea
  • Publication number: 20150010530
    Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 8, 2015
    Inventor: Gary L. Nelsestuen
  • Publication number: 20150010936
    Abstract: The present invention provides a means and method useful for measurement of a total branched-chain amino acid concentration. Specifically, the present invention provides a modified enzyme in which at least one amino acid residue is mutated so as to improve a property of a leucine dehydrogenase which is associated with the measurement of the total branched-chain amino acids, such as, for example, substrate specificities of leucine dehydrogenase for total branched-chain amino acids, activity of leucine dehydrogenase for any branched-chain amino acids, and thermal stability of leucine dehydrogenase; and a method of analyzing the total branched-chain amino acids, comprising measuring the total branched-chain amino acids contained in a test sample using the modified enzyme.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 8, 2015
    Applicant: AJINOMOTO CO., INC.
    Inventors: Wataru Hoshino, Yuya Kodama, Toshimi Mizukoshi, Uno Tagami
  • Publication number: 20150010981
    Abstract: The present invention provides various GH61 protein variants comprising various amino acid substitutions. The GH61 protein variants have an improved ability to synergize with cellulase enzymes, thereby increasing the yield of fermentable sugars obtained by saccharification of biomass. In some embodiments, sugars obtained from saccharification are fermented to produce numerous end-products, including but not limited to alcohol.
    Type: Application
    Filed: September 25, 2014
    Publication date: January 8, 2015
    Inventors: Jie Yang, Xiyun Zhang, Jungjoo Yoon, Kripa K. Rao, John H. Grate, David M. Elgart, Dipnath Baidyaroy
  • Patent number: 8927700
    Abstract: Disclosed herein are amino acid sequences, and encoding nucleotide sequences, of isolated catalytic domains of the LOX and LOXL2 proteins from human and mouse. Methods for the preparation and use of these isolated catalytic domains are also provided.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: January 6, 2015
    Assignee: Gilead Biologics, Inc.
    Inventors: Scott McCauley, Victoria Smith
  • Patent number: 8927248
    Abstract: A modified Family 11 xylanase enzyme comprising cysteine residues at positions 99 and 118 to form an intramolecular disulfide bond is provided. The modified xylanase is produced by substitution of an amino acid at position 99, 118 or both positions 99 and 118 with a cysteine to produce the intramolecular disulfide bond. Xylanases of the invention display improved thermophilicity, alkalophilicity or thermostability relative to wild-type xylanases. Such xylanases find use in a variety of applications in industry that require enzyme activities at temperatures and/or pH values above that of the native enzyme.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: January 6, 2015
    Assignee: National Research Council Canada
    Inventor: Wing L. Sung
  • Patent number: 8926965
    Abstract: The present disclosure provides variant superoxide dismutase polypeptides, compositions comprising the polypeptides, and nucleic acids comprising nucleotide sequences encoding the polypeptides. The present disclosure provides methods of reducing oxidative damage in a cell, tissue, or organ. The present disclosure provides methods of identifying agents that increase superoxide dismutase activity.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: January 6, 2015
    Assignee: The Regents of the University of California
    Inventors: Danica Chen, Xiaolei Qiu
  • Patent number: 8927250
    Abstract: The present invention relates to a polypeptide having alpha-amylase activity obtained from a strain of Aspergillus niger.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: January 6, 2015
    Assignee: Danisco US Inc.
    Inventors: Benjamin S. Bower, Nigel Dunn-Coleman, Suzanne E. Lantz, Cherry Lin, Michael Ward
  • Patent number: 8927036
    Abstract: A process of enzymatic degumming edible oils, comprising treating edible oil with a lipid acyltransferase so as to transfer an acyl group from a major part of the phospholipid to one or more acyl acceptors, wherein the acyl acceptor may be any compound comprising a hydroxyl group. In one embodiment preferably the acyl acceptor is water and in another embodiment preferably the acyl acceptor is one or more sterols and/or stanols. When the acyl acceptor is a stanol and/or sterol, one or more sterol esters and/or stanol esters are produced.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: January 6, 2015
    Assignee: Dupont Nutrition Biosciences APS
    Inventors: Jorn Borch Søe, Mark Turner
  • Publication number: 20150004659
    Abstract: The disclosure relates to a nucleic acid molecule isolated from a Papaver somniferum cultivar that produces the opiate alkaloid noscapine which comprises 10 genes involved in the biosynthesis of opiate alkaloids.
    Type: Application
    Filed: March 12, 2013
    Publication date: January 1, 2015
    Applicant: GlaxoSmithKline Australia Pty Limited
    Inventors: Thilo Winzer, Ian Alexander Graham, Tracy Carol Walker
  • Publication number: 20150004655
    Abstract: The present invention relates to cellobiohydrolase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of producing and using the variants.
    Type: Application
    Filed: December 20, 2012
    Publication date: January 1, 2015
    Inventor: Mark Wogulis
  • Publication number: 20150005168
    Abstract: The present invention refers to a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of providing, at said site, a plant that comprises at least one nucleic acid comprising a nucleotide sequence encoding a wild-type hydroxyphenyl pyruvate dioxygenase or a mutated hydroxyphenyl pyruvate dioxygenase (mut-HPPD) which is resistant or tolerant to a coumarone-derivative herbicide and/or a nucleotide sequence encoding a wild-type homogentisate solanesyl transferase or a mutated homogentisate solanesyl transferase (mut-HST) which is resistant or tolerant to a coumarone-derivative herbicide, and applying to said site an effective amount of said herbicide. The invention further refers to plants comprising mut-HPPD, and methods of obtaining such plants.
    Type: Application
    Filed: October 31, 2012
    Publication date: January 1, 2015
    Applicant: BASF SE
    Inventors: Johannes Hutzler, Stefan Tresch, Thomas Mietzner, Matthias Witschel, Jens Lerchl, Raphael Aponte, Liliana Parra Rapado, Jill Marie Paulik
  • Publication number: 20150007368
    Abstract: Provided are valencene synthase polypeptides, nucleic acid molecules encoding the valencene synthases, host cells containing the nucleic acids and methods for producing products whose production is catalyzed by the polypeptides. Also provided are methods for producing valencene and nootkatone.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 1, 2015
    Inventors: Dayal Saran, Grace Eunyoung Park
  • Publication number: 20150007369
    Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: November 21, 2012
    Publication date: January 1, 2015
    Inventors: Janine Lin, Doreen Bohan, Michelle Maranta, Leslie Beresford, Michael Lamsa, Bjarne Gram Hansen, Frank Winther Rasmussen, Matt Sweeney, Douglas J. Boyle, III
  • Publication number: 20150004656
    Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: September 15, 2014
    Publication date: January 1, 2015
    Inventors: Lan Tang, Ye Liu, Junxin Duan, Yu Zhang, Christian Joergensen, Randall Kramer
  • Publication number: 20150004596
    Abstract: Provided herein in some embodiments is a non-naturally occurring variant of a wild type restriction enzyme defined by SEQ ID NO: 20, wherein the variant has at least a 2 fold increase in cleavage at 5-? glucosylhydroxymethylcytosine (5?ghmC) compared with methylcytosine relative to the wild type enzyme. Methods for examining hydroxymethylation of a DNA sample using the variant enzyme are also provided.
    Type: Application
    Filed: June 27, 2014
    Publication date: January 1, 2015
    Inventors: Zhenyu Zhu, Janine Borgaro, Aine Quimby, Shengxi Guan, Zhiyi Sun
  • Publication number: 20150007363
    Abstract: The subject invention pertains to novel mutant polynucleotide molecules that encode enzymes that have increased heat stability. These polynucleotides, when expressed in plants, result in increased yield in plants grown under conditions of heat stress. The polynucleotide molecules of the subject invention encode maize endosperm ADP glucose pyrophosphorylase (AGP) and soluble starch synthase (SSS) enzyme activities. Plants and plant tissue bred to contain, or transformed with, the mutant polynucleotides, and expressing the polypeptides encoded by the polynucleotides, are also contemplated by the present invention. The subject invention also concerns methods for isolating polynucleotides and polypeptides contemplated within the scope of the invention. Methods for increasing yield in plants grown under conditions of heat stress are also provided.
    Type: Application
    Filed: July 1, 2014
    Publication date: January 1, 2015
    Inventors: L. CURTIS HANNAH, THOMAS W. GREENE
  • Publication number: 20150005370
    Abstract: The present invention discloses the use of a human NLK gene and associated drugs thereof. The present invention discloses the use of the NLK gene for tumor treatment, tumor diagnosis and drug preparation. The present invention further constructs an isolated molecule that attenuates expression of the NLK gene of tumor cells, cells comprising the isolated molecule and a NLK interference lentivirus, and discloses the use thereof as well. The isolated molecule or the NLK interference lentivirus that attenuates expression of the NLK gene provided in the present invention can specifically attenuate expression of the human NLK gene, especially the lentivirus, can effectively infect target cells, efficiently inhibit the expression of the NLK gene in target cells, and inhibit the growth of tumor cells, thus has great significance in tumor treatment.
    Type: Application
    Filed: January 18, 2012
    Publication date: January 1, 2015
    Applicant: SHANGHAI GENECHEM CO., LTD
    Inventors: Haixiong Han, Xiangying Zhu, Qin Sun, Xuefeng Gu, Shenghua Xie, Yang Li, Yangsheng Jin, Honghua Qu, Yueqiong Cao
  • Patent number: 8921043
    Abstract: Compositions and methods are described to modify Family B DNA polymerases that contain residual exonuclease activity that interferes with sequencing techniques and with detection of single nucleotide polymorphisms. The compositions are mutant proteins with reduced exonuclease activity compared with presently available “exo?” polymerases, and a sensitive screening assay that enables an assessment of exonuclease activity of any synthetic DNA polymerase.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: December 30, 2014
    Assignee: New England Biolabs, Inc.
    Inventor: Andrew Gardner
  • Patent number: 8921332
    Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: December 30, 2014
    Assignees: Children's Medical Center Corporation, Institut Pasteur
    Inventors: André Choulika, Richard C. Mulligan
  • Patent number: 8920801
    Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: December 30, 2014
    Assignee: ArmaGen Technologies, Inc.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 8921648
    Abstract: Methods for increasing yield of fermentable sugars from plant stover are provided. The methods include using plants homozygous for two brown midrib mutations, bm1 and bm3. The methods also include using plants homozygous for a mutation in a gene that results in reduced cinnamyl alcohol dehydrogenase activity, and a mutation in a gene that results in reduced 5-hydroxyconiferaldehyde/5-hydroxyconiferyl alcohol O-methyltransferase activity. The methods also include using transgenic plants that have reduced cinnamyl alcohol dehydrogenase activity and reduced 5-hydroxyconiferaldehyde/5-hydroxyconiferyl alcohol O-methyltransferase activity in comparison with wild-type plants.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: December 30, 2014
    Assignee: Purdue Research Foundation
    Inventors: Willem Evert Vermerris, Michael R. Ladisch, Nathan S. Mosier
  • Patent number: 8921044
    Abstract: Compositions and methods are described to modify Family B DNA polymerases that contain residual exonuclease activity that interferes with sequencing techniques and with detection of single nucleotide polymorphisms. The compositions are mutant proteins with reduced exonuclease activity compared with presently available “exo?” polymerases, and a sensitive screening assay that enables an assessment of exonuclease activity of any synthetic DNA polymerase.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: December 30, 2014
    Assignee: New England BioLabs, Inc.
    Inventor: Andrew Gardner